Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase Ib/II study of ricolinostat (ACY-1215) in multiple myeloma (MM) (NCT01997840) presented at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. The trial looks at the combination of ricolinostat with pomalidomide and low-dose dexamethasone in relapsed/refractory multiple myeloma patients. Ricolinostat has a tendancy to be more selective for HDAC6 and according to Dr Raje, it is believed that it is has less off-target toxicity. Dr Raje further explains the rationale of combining with ricolinostat with lenalidomide and discusses data of the Phase Ib/II in 66 patients who have received up to six months of treatment. The data showed an overall response rate of approximately 46% with striking duration of response and progression-free survival (PFS) results. Dr Raje also discusses side effects observed in patients, which were managable.